FY2030 Earnings Estimate for Cybin Issued By HC Wainwright

Cybin Inc. (NYSE:CYBN) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for Cybin in a note issued to investors on Thursday, July 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $6.89 for the year. The consensus estimate for Cybin’s current full-year earnings is ($4.76) per share.

Other equities analysts have also issued reports about the stock. Guggenheim initiated coverage on shares of Cybin in a research report on Thursday, March 13th. They set a “buy” rating and a $35.00 target price on the stock. Cantor Fitzgerald upgraded shares of Cybin to a “strong-buy” rating in a research report on Tuesday, May 13th.

Cybin Trading Up 8.1%

CYBN stock opened at $7.98 on Friday. Cybin has a twelve month low of $4.81 and a twelve month high of $13.88. The company’s 50 day moving average is $7.62 and its two-hundred day moving average is $8.04. The stock has a market cap of $183.62 million, a P/E ratio of -1.82 and a beta of 0.69.

Hedge Funds Weigh In On Cybin

Hedge funds have recently modified their holdings of the business. Tang Capital Management LLC grew its position in Cybin by 232.5% in the 4th quarter. Tang Capital Management LLC now owns 1,330,097 shares of the company’s stock valued at $11,731,000 after buying an additional 930,097 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Cybin in the 4th quarter valued at $7,938,000. Acorn Capital Advisors LLC purchased a new position in Cybin in the 4th quarter valued at $6,477,000. DCF Advisers LLC purchased a new position in Cybin in the 1st quarter valued at $1,281,000. Finally, Knott David M Jr purchased a new position in Cybin in the 4th quarter valued at $533,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.